Related Experiment Videos
Peritoneal dialysis: a viable renal replacement therapy option
1Department of Internal Medicine, Division of Nephrology, UT Southwestern Medical Center, Dallas, Texas 75390-8856, USA. Ramesh.saxena@utsouthwestern.edu
The American Journal of the Medical Sciences
|July 16, 2005
Summary
Peritoneal dialysis (PD) is underutilized despite being cost-effective and offering survival benefits. New biocompatible solutions and therapies may improve long-term outcomes for end-stage renal disease patients on PD.
Area of Science:
- Nephrology
- Biomaterials Science
Background:
- End-stage renal disease (ESRD) patient numbers are rising, increasing demand for dialysis treatments.
- Peritoneal dialysis (PD) is underutilized in the US despite cost-effectiveness and potential survival advantages over hemodialysis.
- Conventional PD solutions can lead to peritoneal membrane damage, limiting long-term treatment efficacy.
Observation:
- PD offers a survival advantage in the initial 2-4 years of treatment.
- This advantage diminishes with age, diabetes, and long-term use due to peritoneal membrane changes.
- Few patients continue PD therapy beyond 10 years.
Findings:
- New biocompatible PD solutions show promise in preserving membrane function and improving ultrafiltration.
- Understanding molecular mechanisms of peritoneal fibrosis and angiogenesis is key.
- Therapeutic strategies targeting these mechanisms could protect the peritoneal membrane.
Implications:
- Biocompatible PD solutions may extend the survival benefit of PD.
- Targeted therapies could mitigate long-term complications, enhancing PD as a viable ESRD treatment.
- Increased PD utilization could improve patient outcomes and reduce healthcare costs.